ArticleScientific reports2016
The role of doxycycline in the therapy of multidrug-resistant E. coli - an in vitro study.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Impact of high frequency electromagnetic radiation on bacterial survival and antibiotic activity in exposed bacteria.Scientific reports · 2025Article
- Doxycycline-Loaded pH-Sensitive Microparticles as a Potential Site-Specific Drug Delivery System against Periodontitis.ACS omega · 2025Article
- Refillable silicone pump with precise switching for timed therapeutic delivery.Frontiers in bioengineering and biotechnology · 2025Article
- Gastrointestinal tract and neuroendocrine system responses of young turkeys to the early administration of antibiotics or feeding a diet containing a coccidiostat.Poultry science · 2022Article
- Constitutive Phenotypic Modification of Lipid A in Clinical Acinetobacter baumannii Isolates.Microbiology spectrum · 2022Article
- The Potential Role of Sulbactam and Cephalosporins Plus Daptomycin Against Daptomycin-Nonsusceptible VISA and H-VISA Isolates: An in Vitro Study.Antibiotics (Basel, Switzerland) · 2019Article
- Drug-Loaded Elastin-Like Polypeptide-Collagen Hydrogels with High Modulus for Bone Tissue Engineering.Macromolecular bioscience · 2019Article
- Extended-spectrum beta-lactamase and Class 1 integrons in multidrug-resistantVeterinary world · 2019Article
- Use of ceragenins as a potential treatment for urinary tract infections.BMC infectious diseases · 2019Article
- The Microbiological Characteristics of Carbapenem-ResistantJournal of clinical medicine · 2019Article
- Antimicrobial Activity ofFrontiers in microbiology · 2019Article
- In vitro activity of cefoperazone and cefoperazone-sulbactam against carbapenem-resistantInfection and drug resistance · 2019Article
- Feline hemotropic mycoplasmosis concurrent with bacterial cystitis in a domestic shorthair cat.Journal of advanced veterinary and animal research · 2018Article
- In vitro activity of minocycline combined with aminoglycosides against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.The Journal of antibiotics · 2018Article
- Appropriate composites of cefoperazone-sulbactam against multidrug-resistant organisms.Infection and drug resistance · 2018Article
- Cephalosporin-Glycopeptide Combinations for Use against Clinical Methicillin-ResistantFrontiers in microbiology · 2017Article
- Doxycycline for Multidrug-Resistant Gram-Negative Bacterial Infection Treatment: A Scoping Review.Journal of global infectious diseasesArticle
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study assessed the in vitro antibacterial activity of combinations of amikacin and doxycycline or tigecycline against multidrug-resistant E. coli isolates. Twenty-four different pulsotypes, including 10 extended-spectrum β-lactamase (ESBL)-, 10 carbapenem-resistant, 2 New Delhi Metallo-beta-lactamase (NDM)- and 2 Klebsiella pneumoniae carbapenemase (KPC)-E. coli isolates were collected. All 24 isolates were susceptible to amikacin and tigecycline. Only 30% of ESBL and 50% of carbapenem-resistant E. coli were susceptible to doxycycline. Both of the NDM-E. coli had a MIC of 64 μg/ml. The checkerboard method showed that for the ESBL- and carbapenem-resistant E. coli, the synergistic effects of amikacin/doxycycline were 80% and 90%, respectively. For the two KPC- and two NDM-E. coli, the FIC index of amikacin/doxycycline were 0.5/0.375 and 0.5/0.281, respectively. For the ESBL- and carbapenem-resistant E. coli isolates, the combinations of amikacin and doxycycline exhibited synergistic activities against 80%, and 80% and 10% vs 60%, and 80% and 10% of the isolates at concentrations of 1x, 1/2x and 1/4xMIC, respectively. The synergistic effect seems to be similar for doxycycline and tigecycline based combinations with amikacin. In conclusion, the antibacterial activity of doxycycline can be enhanced by the addition of amikacin and is observed against most multidrug-resistant E. coli isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.